A Phase I Study of Merestinib Monotherapy or in Combination With Other Anti-Cancer Agents in Japanese Patients With Advanced and/or Metastatic Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2018
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Merestinib (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 06 Jul 2018 Planned End Date changed from 4 Jun 2018 to 1 Sep 2018.
- 06 Jul 2018 Planned primary completion date changed from 4 Jun 2018 to 1 Sep 2018.
- 16 Nov 2017 Status changed from recruiting to active, no longer recruiting.